{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:53:07Z","timestamp":1789656787385,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The SWI\/SNF complex is an important chromatin remodeler, commonly dysregulated in cancer, with an estimated mutation frequency of 20%. ARID1A is the most frequently mutated subunit gene. Almost nothing is known about the other familiar members of the SWI\/SNF complexes, SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1), in oesophageal adenocarcinoma (EAC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed a large cohort of 685 patients with EAC. We used four different antibodies to detect a loss-of-protein of ARID1A BRM, BRG1 and INI1 by immunohistochemistry and correlated these findings with molecular and clinical data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Loss of ARID1A, BRG1, BRM and INI1 was observed in 10.4, 3.4, 9.9 and 2% of EAC. We found a co-existing protein loss of ARID1A and BRM in 9.9% and of ARID1A and BRG1 in 2.2%. Patients with loss of ARID1A and TP53 wildtype EACs showed a shortened overall survival compared with AIRDA1A-positive tumours [median overall survival was 60.1\u2009months (95%CI 1.2\u2013139.9\u2009months)] in patients with ARIDA-1A expression and 26.2\u2009months (95%CI 3.7\u201319.1\u2009months) in cases of ARIDA-1A loss (<jats:italic>p<\/jats:italic>\u00a0=\u20090.044). Tumours with loss or expression of ARID1A and TP53 loss were not associated with a difference in survival. Only one tumour revealed high microsatellite instability (MSI-H) with concomitant ARID1A loss. All other ARID1A loss-EACs were microsatellite-stable (MSS). No predictive relevance was seen for SWI\/SNF-complex alterations and simultaneous amplification of different genes (PIK3CA, KRAS, c-MYC, MET, GATA6, ERBB2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our work describes, for the first time, loss of one of the SWI\/SNF ATPase subunit proteins in a large number of adenocarcinomas of the oesophagus. Several papers discuss possible therapeutic interventions for tumours showing a loss of function of the SWI\/SNF complex, such as PARP inhibitors or PI3K and AKT inhibitors. Future studies will be needed to show whether SWI\/SNF complex-deficient EACs may benefit from personalized therapy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-019-6425-3","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T13:02:40Z","timestamp":1578315760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Loss of the SWI\/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Simon","family":"Schallenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Bork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlem","family":"Essakly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Alakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Buettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel M.","family":"Hillmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Loeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"2","key":"6425_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin"},{"issue":"70","key":"6425_CR2","doi-asserted-by":"publisher","first-page":"115179","DOI":"10.18632\/oncotarget.23112","volume":"8","author":"H Loeser","year":"2017","unstructured":"Loeser H, et al. High protein and mRNA expression levels of TUBB3 (class III ss-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas. Oncotarget. 2017;8(70):115179\u201389.","journal-title":"Oncotarget"},{"issue":"4","key":"6425_CR3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/genetics\/108.4.845","volume":"108","author":"L Neigeborn","year":"1984","unstructured":"Neigeborn L, Carlson M. Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. Genetics. 1984;108(4):845\u201358.","journal-title":"Genetics"},{"issue":"4","key":"6425_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/0022-2836(84)90315-2","volume":"178","author":"M Stern","year":"1984","unstructured":"Stern M, Jensen R, Herskowitz I. Five SWI genes are required for expression of the HO gene in yeast. J Mol Biol. 1984;178(4):853\u201368.","journal-title":"J Mol Biol"},{"key":"6425_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1101\/sqb.2016.81.031021","volume":"81","author":"JL Pulice","year":"2016","unstructured":"Pulice JL, Kadoch C. Composition and function of mammalian SWI\/SNF chromatin remodeling complexes in human disease. Cold Spring Harb Symp Quant Biol. 2016;81:53\u201360.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"2","key":"6425_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1097-2765(00)80315-9","volume":"3","author":"ML Phelan","year":"1999","unstructured":"Phelan ML, et al. Reconstitution of a core chromatin remodeling complex from SWI\/SNF subunits. Mol Cell. 1999;3(2):247\u201353.","journal-title":"Mol Cell"},{"issue":"14","key":"6425_CR7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/onc.2009.4","volume":"28","author":"D Reisman","year":"2009","unstructured":"Reisman D, Glaros S, Thompson EA. The SWI\/SNF complex and cancer. Oncogene. 2009;28(14):1653\u201368.","journal-title":"Oncogene"},{"key":"6425_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","volume":"78","author":"CR Clapier","year":"2009","unstructured":"Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem. 2009;78:273\u2013304.","journal-title":"Annu Rev Biochem"},{"key":"6425_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pharmthera.2018.05.001","volume":"190","author":"R Mathur","year":"2018","unstructured":"Mathur R. ARID1A loss in cancer: towards a mechanistic understanding. Pharmacol Ther. 2018;190:15\u201323.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"6425_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/sj.onc.1205188","volume":"21","author":"DN Reisman","year":"2002","unstructured":"Reisman DN, et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene. 2002;21(8):1196\u2013207.","journal-title":"Oncogene"},{"issue":"3","key":"6425_CR11","first-page":"560","volume":"63","author":"DN Reisman","year":"2003","unstructured":"Reisman DN, et al. Loss of BRG1\/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 2003;63(3):560\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"6425_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055119","volume":"8","author":"AH Shain","year":"2013","unstructured":"Shain AH, Pollack JR. The spectrum of SWI\/SNF mutations, ubiquitous in human cancers. PLoS One. 2013;8(1):e55119.","journal-title":"PLoS One"},{"issue":"8","key":"6425_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/gcc.20459","volume":"46","author":"J Huang","year":"2007","unstructured":"Huang J, et al. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer. 2007;46(8):745\u201350.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"6425_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/path.4247","volume":"231","author":"IY Chong","year":"2013","unstructured":"Chong IY, et al. The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol. 2013;231(3):301\u201310.","journal-title":"J Pathol"},{"issue":"3","key":"6425_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/onc.2012.586","volume":"33","author":"MM Streppel","year":"2014","unstructured":"Streppel MM, et al. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene. 2014;33(3):347\u201357.","journal-title":"Oncogene"},{"issue":"5","key":"6425_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ng.2591","volume":"45","author":"AM Dulak","year":"2013","unstructured":"Dulak AM, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45(5):478\u201386.","journal-title":"Nat Genet"},{"issue":"12","key":"6425_CR17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/ng.982","volume":"43","author":"K Wang","year":"2011","unstructured":"Wang K, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219\u201323.","journal-title":"Nat Genet"},{"issue":"1","key":"6425_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/humu.21633","volume":"33","author":"S Jones","year":"2012","unstructured":"Jones S, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33(1):100\u20133.","journal-title":"Hum Mutat"},{"issue":"5","key":"6425_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/ng.2246","volume":"44","author":"ZJ Zang","year":"2012","unstructured":"Zang ZJ, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44(5):570\u20134.","journal-title":"Nat Genet"},{"issue":"7","key":"6425_CR20","doi-asserted-by":"publisher","first-page":"970","DOI":"10.5858\/arpa.2016-0318-OA","volume":"141","author":"MG Drage","year":"2017","unstructured":"Drage MG, et al. Morphological features and prognostic significance of ARID1A-deficient esophageal adenocarcinomas. Arch Pathol Lab Med. 2017;141(7):970\u20137.","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"6425_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ijc.20450","volume":"112","author":"X Wang","year":"2004","unstructured":"Wang X, et al. Expression of p270 (ARID1A), a component of human SWI\/SNF complexes, in human tumors. Int J Cancer. 2004;112(4):636.","journal-title":"Int J Cancer"},{"issue":"3","key":"6425_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nm.3480","volume":"20","author":"KC Helming","year":"2014","unstructured":"Helming KC, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014;20(3):251\u20134.","journal-title":"Nat Med"},{"issue":"5","key":"6425_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556\u201362.","journal-title":"Nat Med"},{"issue":"2","key":"6425_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.sla.0000245847.40779.10","volume":"245","author":"AH Holscher","year":"2007","unstructured":"Holscher AH, et al. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg. 2007;245(2):241\u20136.","journal-title":"Ann Surg"},{"issue":"6","key":"6425_CR25","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/SLA.0b013e31818f3afb","volume":"248","author":"PM Schneider","year":"2008","unstructured":"Schneider PM, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248(6):902\u20138.","journal-title":"Ann Surg"},{"key":"6425_CR26","first-page":"257","volume":"114","author":"R Simon","year":"2005","unstructured":"Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Med. 2005;114:257\u201368.","journal-title":"Methods Mol Med"},{"issue":"16","key":"6425_CR27","doi-asserted-by":"publisher","first-page":"21763","DOI":"10.18632\/oncotarget.7845","volume":"7","author":"D Helbig","year":"2016","unstructured":"Helbig D, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7(16):21763\u201374.","journal-title":"Oncotarget"},{"issue":"3","key":"6425_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00292-010-1278-1","volume":"31","author":"J Ruschoff","year":"2010","unstructured":"Ruschoff J, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe. 2010;31(3):208\u201317.","journal-title":"Pathologe"},{"issue":"1","key":"6425_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12885-018-5242-4","volume":"19","author":"PS Plum","year":"2019","unstructured":"Plum PS, et al. HER2\/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer. 2019;19(1):38.","journal-title":"BMC Cancer"},{"issue":"1","key":"6425_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.tranon.2018.09.007","volume":"12","author":"A Quaas","year":"2019","unstructured":"Quaas A, et al. Genomic characterization of TP53-wild-type esophageal carcinoma. Transl Oncol. 2019;12(1):154\u201361.","journal-title":"Transl Oncol"},{"key":"6425_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejca.2018.02.014","volume":"94","author":"LC Hewitt","year":"2018","unstructured":"Hewitt LC, et al. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: a large multi-Centre study. Eur J Cancer. 2018;94:104\u201314.","journal-title":"Eur J Cancer"},{"issue":"1","key":"6425_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00428-018-2317-1","volume":"472","author":"S Biswas","year":"2018","unstructured":"Biswas S, et al. The metaplastic mosaic of Barrett's oesophagus. Virchows Arch. 2018;472(1):43\u201354.","journal-title":"Virchows Arch"},{"issue":"5","key":"6425_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrm2146","volume":"8","author":"JM Slack","year":"2007","unstructured":"Slack JM. Metaplasia and transdifferentiation: from pure biology to the clinic. Nat Rev Mol Cell Biol. 2007;8(5):369\u201378.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"6425_CR34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","volume":"21","author":"HU Schildhaus","year":"2015","unstructured":"Schildhaus HU, et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2015;21(4):907\u201315.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6425_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cancergencyto.2007.10.011","volume":"181","author":"LC Costa Raiol","year":"2008","unstructured":"Costa Raiol LC, et al. Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. Cancer Genet Cytogenet. 2008;181(1):31\u20135.","journal-title":"Cancer Genet Cytogenet"},{"issue":"9","key":"6425_CR36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00432-018-2698-1","volume":"144","author":"PS Plum","year":"2018","unstructured":"Plum PS, et al. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus. J Cancer Res Clin Oncol. 2018;144(9):1731\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"6425_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4161\/cbt.28411","volume":"15","author":"RC Wu","year":"2014","unstructured":"Wu RC, Wang TL, Shih Ie M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655\u201364.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"6425_CR38","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3748\/wjg.v21.i7.2159","volume":"21","author":"R Inada","year":"2015","unstructured":"Inada R, et al. ARID1A expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status. World J Gastroenterol. 2015;21(7):2159\u201368.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"6425_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00428-012-1303-2","volume":"461","author":"H Abe","year":"2012","unstructured":"Abe H, et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch. 2012;461(4):367\u201377.","journal-title":"Virchows Arch"},{"issue":"9","key":"6425_CR40","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/bjc.1997.226","volume":"75","author":"F Muzeau","year":"1997","unstructured":"Muzeau F, et al. Infrequent microsatellite instability in oesophageal cancers. Br J Cancer. 1997;75(9):1336\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"6425_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cancergencyto.2004.08.003","volume":"157","author":"D Falkenback","year":"2005","unstructured":"Falkenback D, et al. Defective mismatch-repair as a minor tumorigenic pathway in Barrett esophagus-associated adenocarcinoma. Cancer Genet Cytogenet. 2005;157(1):82\u20136.","journal-title":"Cancer Genet Cytogenet"},{"issue":"7","key":"6425_CR42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen J, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5(7):752\u201367.","journal-title":"Cancer Discov"},{"issue":"11","key":"6425_CR43","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1101\/gr.137596.112","volume":"22","author":"H Liang","year":"2012","unstructured":"Liang H, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22(11):2120\u20139.","journal-title":"Genome Res"},{"key":"6425_CR44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2407-14-120","volume":"14","author":"KC Wiegand","year":"2014","unstructured":"Wiegand KC, et al. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A\/BAF250a is associated with AKT phosphorylation. BMC Cancer. 2014;14:120.","journal-title":"BMC Cancer"},{"issue":"14","key":"6425_CR45","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.18632\/oncotarget.2092","volume":"5","author":"EP Samartzis","year":"2014","unstructured":"Samartzis EP, et al. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget. 2014;5(14):5295\u2013303.","journal-title":"Oncotarget"},{"issue":"3","key":"6425_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler BG, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"6425_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","volume":"35","author":"H Ogiwara","year":"2019","unstructured":"Ogiwara H, et al. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. Cancer Cell. 2019;35(2):177\u2013190.e8.","journal-title":"Cancer Cell"},{"issue":"1","key":"6425_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40792-019-0562-4","volume":"5","author":"H Nagano","year":"2019","unstructured":"Nagano H, et al. SMARCB1- and vimentin-positive esophageal carcinoma with undifferentiated components, rhabdoid features, and a good prognosis: a case report. Surg Case Rep. 2019;5(1):8.","journal-title":"Surg Case Rep"},{"issue":"10","key":"6425_CR49","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/0008-5472.CAN-18-1545","volume":"79","author":"T Shorstova","year":"2019","unstructured":"Shorstova T, et al. SWI\/SNF-compromised cancers are susceptible to Bromodomain inhibitors. Cancer Res. 2019;79(10):2761\u201374.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6425-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T07:34:22Z","timestamp":1613374462000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6425"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6425-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"25 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Procedures were followed as outlined in accordance with ethical standards formulated in the Helsinki Declaration 1975 (and revised in 1983). Patients gave their written consent to usage of their tumor specimens and the objective of the project is primarily in the field of diagnostics and quality assurance, an approval was obtained from the University of Cologne Ethics Committee (reference number: 13\u2013091 and 10\u2013242; Lehmann and Grass et al).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}